Scopus Biopharma Correlations
| SCPSDelisted Stock | USD 0.10 0.00 0.00% |
The current 90-days correlation between Scopus Biopharma and Pasithea Therapeutics Corp is -0.07 (i.e., Good diversification). The correlation of Scopus Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Scopus Biopharma Correlation With Market
Average diversification
The correlation between Scopus Biopharma and DJI is 0.18 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Scopus Biopharma and DJI in the same portfolio, assuming nothing else is changed.
Scopus |
The ability to find closely correlated positions to Scopus Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Scopus Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Scopus Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Scopus Biopharma to buy it.
Moving together with Scopus OTC Stock
Moving against Scopus OTC Stock
| 0.61 | FRTX | Fresh Tracks Therapeutics | PairCorr |
| 0.4 | VAXX | Vaxxinity | PairCorr |
| 0.4 | ZVRA | Zevra Therapeutics | PairCorr |
| 0.37 | ZYME | Zymeworks Common Stock | PairCorr |
| 0.34 | GRCE | Grace Therapeutics, Symbol Change | PairCorr |
| 0.56 | ESLAW | Estrella Immunopharma | PairCorr |
| 0.46 | ITRM | Iterum Therapeutics PLC | PairCorr |
| 0.33 | RVMDW | Revolution Medicines, | PairCorr |
Related Correlations Analysis
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Scopus OTC Stock performing well and Scopus Biopharma OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Scopus Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| SCPH | 2.76 | (0.63) | 0.00 | (0.24) | 0.00 | 4.30 | 20.70 | |||
| DMAC | 2.47 | 0.46 | 0.15 | 33.37 | 2.00 | 5.20 | 14.14 | |||
| MNPR | 20.49 | 10.68 | 0.91 | (2.42) | 7.84 | 15.93 | 653.56 | |||
| KTTA | 5.14 | (0.40) | 0.00 | (0.68) | 0.00 | 8.27 | 68.44 | |||
| MTCR | 2.54 | 0.32 | 0.02 | (0.14) | 2.49 | 9.09 | 21.01 | |||
| MGTA | 2.62 | 0.06 | 0.00 | 0.26 | 3.40 | 5.88 | 16.99 | |||
| TARA | 3.37 | 0.65 | 0.17 | 3.43 | 2.78 | 8.67 | 19.48 | |||
| TCON | 6.84 | (1.55) | 0.00 | 0.72 | 0.00 | 19.59 | 52.05 | |||
| STSA | 3.39 | 0.41 | 0.09 | 0.62 | 3.54 | 5.71 | 70.12 | |||
| CDAKQ | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
View Scopus Biopharma Related Equities
| Risk & Return | Correlation |
Scopus Biopharma Corporate Management
Elected by the shareholders, the Scopus Biopharma's board of directors comprises two types of representatives: Scopus Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Scopus. The board's role is to monitor Scopus Biopharma's management team and ensure that shareholders' interests are well served. Scopus Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Scopus Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ira Greenspan | Advisor Director | Profile | |
| David Silberg | Advisor | Profile | |
| Robert Gibson | S Chairman | Profile | |
| Alan Horsager | PresofImmunoOncology BioTherapeutics | Profile |
Still Interested in Scopus Biopharma?
Investing in delisted otcs can be risky, as the otc stock is no longer traded on a public exchange and can therefore be difficult to sell. Delisting typically occurs when a company has failed to meet exchange requirements or has been acquired. Before investing, it's important to thoroughly research the company, including its financial health and prospects for the future, as well as the reasons for its delisting. Additionally, it may be difficult to find accurate and up-to-date information on the company and its stock.